{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T23:01:49Z","timestamp":1784502109090,"version":"3.55.0"},"reference-count":29,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,7,20]],"date-time":"2026-07-20T00:00:00Z","timestamp":1784505600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Genet."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Small-cell lung cancer (SCLC) is an aggressive malignancy with poor survival outcomes. Biomarkers that reliably capture tumor mutational burden (TMB), tumor immunogenicity, and prognosis could substantially improve clinical stratification. Prior studies have suggested that mutational signatures, including single-base substitution (SBS) 4 and 13, may be associated with TMB and survival in SCLC. We therefore evaluated these relationships using complementary analytical approaches.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We evaluated associations among mutational signatures, TMB, and overall survival in a dataset examined in a prior study and an independent external cohort. To improve reproducibility and interpretability, we performed reference-based mutational signature assignment and analyzed signature activity, primarily as a continuous variable, while also evaluating binary stratifications using fixed thresholds. Signature\u2013TMB relationships were assessed using continuous regression models, and associations with overall survival were evaluated pooling all clinically annotated samples using Kaplan-Meier analysis and Cox-proportional-hazards modeling.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Across both cohorts, SBS4 activity was positively associated with TMB, whereas SBS13 showed no consistent relationship with TMB. Neither SBS4 nor SBS13 was a statistically significant predictor of overall survival.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Our study clarifies the prognostic and immunogenomic relevance of SBS4 and SBS13 in SCLC and shows that analytical choices materially influence inference. Reference-based signature assignment provided a comprehensive, computationally efficient, and stable framework, while continuous measures of signature activity yielded more reliable inferences than arbitrary thresholds. These findings support more rigorous evaluation of mutational signatures and TMB as biomarkers in SCLC.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fgene.2026.1776578","type":"journal-article","created":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T22:10:20Z","timestamp":1784499020000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Evaluating the prognostic value of mutational signatures in small-cell lung cancer through reference-based signature assignment and continuous activity analysis"],"prefix":"10.3389","volume":"17","author":[{"given":"Rishabh","family":"Garg","sequence":"first","affiliation":[{"name":"Yale College","place":["New Haven, CT, United States"]},{"name":"Department of Biostatistics, Yale School of Public Health","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kira A.","family":"Glasmacher","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale School of Public Health","place":["New Haven, CT, United States"]},{"name":"Program in Computational Biology and Biomedical Informatics, Yale University","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arnaud","family":"Augert","sequence":"additional","affiliation":[{"name":"Department of Pathology, Yale School of Medicine, Yale University","place":["New Haven, CT, United States"]},{"name":"Yale Cancer Center","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey P.","family":"Townsend","sequence":"additional","affiliation":[{"name":"Department of Biostatistics, Yale School of Public Health","place":["New Haven, CT, United States"]},{"name":"Program in Computational Biology and Biomedical Informatics, Yale University","place":["New Haven, CT, United States"]},{"name":"Yale Cancer Center","place":["New Haven, CT, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,7,20]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"618","DOI":"10.1126\/science.aag0299","article-title":"Mutational signatures associated with tobacco smoking in human cancer","volume":"354","author":"Alexandrov","year":"2016","journal-title":"Science"},{"key":"B2","doi-asserted-by":"publisher","first-page":"94","DOI":"10.1038\/s41586-020-1943-3","article-title":"The repertoire of mutational signatures in human cancer","volume":"578","author":"Alexandrov","year":"2020","journal-title":"Nature"},{"key":"B3","article-title":"Small cell lung cancer","volume-title":"StatPearls","author":"Basumallik","year":"2025"},{"key":"B4","doi-asserted-by":"publisher","first-page":"msac084","DOI":"10.1093\/molbev\/msac084","article-title":"Attribution of cancer origins to endogenous, exogenous, and preventable mutational processes","volume":"39","author":"Cannataro","year":"2022","journal-title":"Mol. Biol. Evol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"6655","DOI":"10.1038\/s41467-021-26821-8","article-title":"Cold and heterogeneous T cell repertoire is associated with copy number aberrations and loss of immune genes in small-cell lung cancer","volume":"12","author":"Chen","year":"2021","journal-title":"Nat. Commun."},{"key":"B6","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1177\/014662168300700301","article-title":"The cost of dichotomization","volume":"7","author":"Cohen","year":"1983","journal-title":"Appl. Psychol. Meas."},{"key":"B7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/nature14664","article-title":"Comprehensive genomic profiles of small cell lung cancer","volume":"524","author":"George","year":"2015","journal-title":"Nature"},{"key":"B8","doi-asserted-by":"publisher","first-page":"880","DOI":"10.1038\/s41586-024-07177-7","article-title":"Evolutionary trajectories of small cell lung cancer under therapy","volume":"627","author":"George","year":"2024","journal-title":"Nature"},{"key":"B9","doi-asserted-by":"publisher","first-page":"e81699","DOI":"10.1371\/journal.pone.0081699","article-title":"Do optimal prognostic thresholds in continuous physiological variables really exist? Analysis of origin of apparent thresholds, with systematic review for peak oxygen consumption, ejection fraction and BNP","volume":"9","author":"Giannoni","year":"2014","journal-title":"PLoS One"},{"key":"B10","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1038\/nrc1190","article-title":"Tobacco carcinogens, their biomarkers and tobacco-induced cancer","volume":"3","author":"Hecht","year":"2003","journal-title":"Nat. Rev. Cancer"},{"key":"B11","doi-asserted-by":"publisher","first-page":"853","DOI":"10.1016\/j.ccell.2018.04.001","article-title":"Tumor mutational burden and efficacy of nivolumab monotherapy and in combination with ipilimumab in small-cell lung cancer","volume":"33","author":"Hellmann","year":"2018","journal-title":"Cancer Cell"},{"key":"B12","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1056\/nejmoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B13","doi-asserted-by":"publisher","first-page":"e1005895","DOI":"10.1371\/journal.pgen.1005895","article-title":"Genomic landscape survey identifies SRSF1 as a key oncodriver in small cell lung cancer","volume":"12","author":"Jiang","year":"2016","journal-title":"PLoS Genet."},{"key":"B14","doi-asserted-by":"publisher","first-page":"15592","DOI":"10.1038\/s41598-025-00222-z","article-title":"Novel prognostic biomarkers in small cell lung cancer reveal mutational signatures, genomic mutations, and immune implications","volume":"15","author":"Li","year":"2025","journal-title":"Sci. Rep."},{"key":"B15","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.cell.2023.12.004","article-title":"Proteogenomic characterization of small cell lung cancer identifies biological insights and subtype-specific therapeutic strategies","volume":"187","author":"Liu","year":"2024","journal-title":"Cell"},{"key":"B16","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1158\/0008-5472.can-22-1508","article-title":"Estimation of neutral mutation rates and quantification of somatic variant selection using cancereffectsizeR","volume":"83","author":"Mandell","year":"2023","journal-title":"Cancer Res."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12864-022-08357-3","article-title":"MutationalPatterns: the one stop shop for the analysis of mutational processes","volume":"23","author":"Manders","year":"2022","journal-title":"BMC Genomics"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1353","DOI":"10.1016\/S1470-2045(20)30445-9","article-title":"Association of tumour mutational burden with outcomes in patients with advanced solid tumours treated with pembrolizumab: prospective biomarker analysis of the multicohort, open-label, phase 2 KEYNOTE-158 study","volume":"21","author":"Marabelle","year":"2020","journal-title":"Lancet Oncol."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1049501","DOI":"10.3389\/fgene.2022.1049501","article-title":"Unravelling the instability of mutational signatures extraction via archetypal analysis","volume":"13","author":"Pancotti","year":"2023","journal-title":"Front. Genet."},{"key":"B20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s13059-016-0893-4","article-title":"deconstructSigs: delineating mutational processes in single tumors distinguishes DNA repair deficiencies and patterns of carcinoma evolution","volume":"17","author":"Rosenthal","year":"2016","journal-title":"Genome Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/ng.2405","article-title":"Comprehensive genomic analysis identifies SOX2 as a frequently amplified gene in small-cell lung cancer","volume":"44","author":"Rudin","year":"2012","journal-title":"Nat. Genet."},{"key":"B22","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1038\/s41572-020-00235-0","article-title":"Small-cell lung cancer","volume":"7","author":"Rudin","year":"2021","journal-title":"Nat. Reviews Dis. Primers"},{"key":"B23","doi-asserted-by":"publisher","first-page":"265","DOI":"10.1016\/j.lungcan.2021.10.008","article-title":"Heavy mutagenesis by tobacco leads to lung adenocarcinoma tumors with KRAS G12 mutations other than G12D, leading KRAS G12D tumors-on average-to exhibit a lower mutation burden","volume":"166","author":"Tan","year":"2022","journal-title":"Lung Cancer"},{"key":"B24","doi-asserted-by":"publisher","first-page":"891938","DOI":"10.3389\/fonc.2022.891938","article-title":"Whole-exome sequencing uncovers specific genetic variation difference based on different modes of drug resistance in small cell lung cancer","volume":"12","author":"Tang","year":"2022","journal-title":"Front. Oncol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/s43018-025-00996-1","article-title":"Advancing therapeutics in small-cell lung cancer","volume":"6","author":"Thomas","year":"2025","journal-title":"Nat. Cancer"},{"key":"B26","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1038\/s41588-020-00752-4","article-title":"The association between tumor mutational burden and prognosis is dependent on treatment context","volume":"53","author":"Valero","year":"2021","journal-title":"Nat. Genet."},{"key":"B27","doi-asserted-by":"publisher","first-page":"665","DOI":"10.1111\/cas.15606","article-title":"Molecular subtyping of small-cell lung cancer based on mutational signatures with different genomic features and therapeutic strategies","volume":"114","author":"Wang","year":"2023","journal-title":"Cancer Sci."},{"key":"B28","doi-asserted-by":"publisher","first-page":"bbad331","DOI":"10.1093\/bib\/bbad331","article-title":"Mutational signature assignment heterogeneity is widespread and can be addressed by ensemble approaches","volume":"24","author":"Wu","year":"2023","journal-title":"Brief. Bioinform"},{"key":"B29","doi-asserted-by":"publisher","first-page":"5431","DOI":"10.1038\/s41467-021-25787-x","article-title":"Multi-region exome sequencing reveals the intratumoral heterogeneity of surgically resected small cell lung cancer","volume":"12","author":"Zhou","year":"2021","journal-title":"Nat. Commun."}],"container-title":["Frontiers in Genetics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1776578\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,19]],"date-time":"2026-07-19T22:10:21Z","timestamp":1784499021000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fgene.2026.1776578\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,20]]},"references-count":29,"alternative-id":["10.3389\/fgene.2026.1776578"],"URL":"https:\/\/doi.org\/10.3389\/fgene.2026.1776578","relation":{},"ISSN":["1664-8021"],"issn-type":[{"value":"1664-8021","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7,20]]},"article-number":"1776578"}}